RISDIPLAM ACTIVE INGREDIENT "EVRYSDI 0.75 mg/mL POWDER FOR PREPARING ORAL SOLUTION, 80 ML" HIS TREATMENT HAS BEEN LICENSED IN OUR COUNTRY.

To Prepare Evrysdi 0.75 mg/mL Oral Solution with the active ingredient Risdiplam, which is one of the 3 different treatment methods approved by EMA (European Medicines Agency) and FDA (American Food and Drug Administration) in the treatment of SMA disease. Powder, 80 ML treatment has been licensed in our country.

The registration information of the drug, which SMA patients have been waiting for with hope for a long time, is available on 18.10.2024, TITCK (Turkish Medicines and Medical Devices Agency) official page.

Licensing of Evrysdi treatment taken orally after Spinraza treatment, which is within the scope of reimbursement in our country. It has been an important stage for SMA patients to hold on to life. Our wish; In the coming days, the issue of which types of patients and which age groups will benefit will be clarified with the SUT (Health Practice Communiqué) and the process of including the drug within the scope of reimbursement will be completed quickly.